PITX2 and neoplasm: Given that RGS interferes with RAS-RAF activation and triggers CD40-dependent anti-tumor effects in melanoma, we questioned whether the CD40 level is prognostic of response to previously used effective therapy, such as RAF inhibitor treatment.